Equities research analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to announce earnings per share (EPS) of $1.77 for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Zimmer Biomet Holdings’ earnings, with the highest EPS estimate coming in at $1.93 and the lowest estimate coming in at $1.73. Zimmer Biomet Holdings posted earnings per share of $1.79 during the same quarter last year, which indicates a negative year over year growth rate of 1.1%. The firm is scheduled to issue its next earnings results on Monday, October 30th.

According to Zacks, analysts expect that Zimmer Biomet Holdings will report full-year earnings of $8.26 per share for the current financial year, with EPS estimates ranging from $8.20 to $8.55. For the next fiscal year, analysts expect that the firm will report earnings of $8.83 per share, with EPS estimates ranging from $8.55 to $9.38. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Zimmer Biomet Holdings.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 EPS.

A number of analysts recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC reissued a “buy” rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $136.75.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 115.70 on Friday. The company has a market cap of $23.39 billion, a P/E ratio of 32.95 and a beta of 1.21. The stock’s 50 day moving average price is $116.64 and its 200 day moving average price is $120.78. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

In related news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the business. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% during the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 22 shares during the period. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet Holdings during the second quarter valued at approximately $144,000. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% during the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 199 shares during the period. Finally, IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% during the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 256 shares during the period. Institutional investors and hedge funds own 85.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/09/zacks-analysts-anticipate-zimmer-biomet-holdings-inc-zbh-to-post-1-77-earnings-per-share.html.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet Holdings (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.